한글목차

크립토코쿠스증 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 41억 3,000만 달러에서 2026년에는 43억 6,000만 달러로, CAGR 5.6%로 확대될 전망입니다. 지난 몇 년간의 성장 요인으로는 항진균제의 제한된 가용성, 면역 결핍 환자의 높은 유병률, 병원 기반 치료에 대한 의존도, 브랜드 의약품의 우위, 경구용 제제의 도입 지연 등을 꼽을 수 있습니다.

크립토코쿠스증 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 53억 3,000만 달러에 달하고, CAGR은 5.2%를 기록할 전망입니다. 예측 기간 동안 성장 요인으로는 개발도상국의 크립토코쿠스증 발생률 증가, 신규 항진균제 개발, 의료진의 인식 개선, 온라인 약국 채널 확대, 병용요법 및 표적치료에 대한 투자 증가 등이 꼽힙니다. 예측 기간 동안 주요 동향으로는 제네릭 항진균제 채택 증가, 중증 환자에서 정맥 투여 선호도 증가, 온라인 및 소매 약국 유통 채널 확대, 크립토코커스 증의 조기 진단 및 치료에 대한 관심 증가, 병용요법 및 신규 제제 개발 등이 있습니다.

인간면역결핍바이러스(HIV) 또는 후천성면역결핍증후군(AIDS)의 유병률 증가는 향후 몇 년 동안 크립토코쿠스증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. HIV/AIDS는 인체의 면역체계를 약화시키는 바이러스에 의해 발생하는 만성적이고 생명을 위협하는 질병으로, 환자는 기회감염 및 기타 질병에 매우 취약한 상태에 놓이게 됩니다. 의료 서비스에 대한 접근성이 제한된 지역에서는 적시에 진단, 지속적인 치료, 효과적인 예방책의 시행이 어려워 HIV/AIDS의 유병률이 증가하고 있습니다. 크립토코쿠스증 치료제는 면역결핍 환자에서 빈번하게 발생하는 기회진균 감염을 치료함으로써 HIV/AIDS 관리에 있어 매우 중요한 역할을 합니다. 이러한 치료법은 크립토코커스 수막염과 같은 심각한 합병증 위험을 줄이고 임상 결과를 개선하여 삶의 질을 높이고 장기적인 질병 관리를 돕습니다. 예를 들어, 영국 정부 기관인 영국 보건안전청(UK Health Security Agency)에 따르면, 2024년 10월 기준, 2023년 영국에서 보고된 HIV 신규 진단 건수는 6,008건(해외에서 이전에 진단받은 사람 포함)으로 2022년 3,975건보다 51% 증가했습니다.에서 51% 증가했습니다. 따라서 HIV/AIDS의 유병률 증가가 크립토코쿠스증 치료제 시장의 성장에 기여하고 있습니다.

헬스케어 지출 증가도 향후 크립토코쿠스증 치료제 시장 확대를 견인할 것으로 예상됩니다. 헬스케어 지출은 의료 서비스, 치료, 의료 인프라, 연구 및 건강 상태 개선을 위한 공중 보건 프로그램에 대한 총 지출을 의미합니다. 의료비 지출 증가는 주로 고령화되는 세계 인구에 의해 주도되고 있으며, 이는 의료, 첨단 치료 및 장기적인 건강 서비스에 대한 수요를 증가시키고 있습니다. 의료비 지출의 증가는 고급 항진균 치료에 대한 접근성 향상, 조기 진단의 실현, 보다 효과적인 치료법에 대한 연구 자금 지원을 통해 크립토코쿠스증 치료제 시장을 뒷받침하고 있습니다. 예를 들어, 미국 연방 기관인 메디케어-메디케이드 서비스 센터(CMS)에 따르면, 2024년 12월 기준 2023년 국내 의료비 지출은 7.5% 증가한 4조 9,000억 달러로 국내총생산(GDP)의 17.6%를 차지할 것으로 예상했습니다. 또한, 2023년부터 2032년까지 연평균 성장률은 5.6%로 예측되며, GDP 대비 의료비 비중은 2022년 17.3%에서 2032년까지 19.7%로 상승할 것으로 예상됩니다. 따라서 헬스케어 비용의 증가가 크립토코쿠스증 치료제 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Cryptococcosis therapeutics encompass the range of medical treatments used to manage cryptococcosis, a potentially life-threatening fungal infection primarily caused by Cryptococcus neoformans or Cryptococcus gattii, which most often affects individuals with weakened immune systems. The primary goal of these therapies is to control the spread of the fungus, alleviate symptoms, and prevent serious complications such as meningitis.

The main drug types of cryptococcosis therapeutics include branded and generic medications. Branded drugs are prescription treatments marketed under a proprietary, trademark-protected name by pharmaceutical companies. These therapies include agents such as amphotericin B, flucytosine, fluconazole, and others, and are administered through oral, intravenous, and inhalation routes. Cryptococcosis therapeutics are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by various end users, including hospitals, ambulatory surgical centers, and others.

Tariffs have affected the cryptococcosis therapeutics market by increasing the cost of imported antifungal drugs and active pharmaceutical ingredients (APIs). Segments such as branded drugs and intravenous formulations are particularly impacted, with Asia-Pacific regions including India and China facing higher import duties. This has led to elevated treatment costs and temporary supply shortages. On the positive side, tariffs have encouraged local drug manufacturing, investment in domestic production capabilities, and accelerated development of generic alternatives.

The cryptococcosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides cryptococcosis therapeutics market statistics, including cryptococcosis therapeutics industry global market size, regional shares, competitors with a cryptococcosis therapeutics market share, detailed cryptococcosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis therapeutics industry. This cryptococcosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cryptococcosis therapeutics market size has grown strongly in recent years. It will grow from $4.13 billion in 2025 to $4.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to limited availability of antifungal therapeutics, high prevalence of immunocompromised patients, reliance on hospital-based treatment, predominance of branded drugs, slow adoption of oral formulations.

The cryptococcosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.33 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing incidence of cryptococcosis in developing regions, development of novel antifungal agents, rising awareness among healthcare providers, expansion of online pharmacy channels, growing investment in combination and targeted therapies. Major trends in the forecast period include rising adoption of generic antifungal drugs, increasing preference for intravenous administration in severe cases, expansion of online and retail pharmacy distribution channels, growing focus on early diagnosis and treatment of cryptococcosis, development of combination therapies and novel formulations.

The increasing prevalence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) is anticipated to drive the growth of the cryptococcosis therapeutics market in the coming years. HIV/AIDS is a chronic and life-threatening condition caused by a virus that weakens the body's immune system, making individuals highly susceptible to opportunistic infections and other diseases. The prevalence of HIV/AIDS is rising in certain regions due to limited access to healthcare services, which restricts timely diagnosis, continuous treatment, and effective prevention measures. Cryptococcosis therapeutics play a vital role in managing HIV/AIDS by treating opportunistic fungal infections that frequently affect immunocompromised patients. These therapies improve clinical outcomes by lowering the risk of severe complications such as cryptococcal meningitis, thereby enhancing quality of life and supporting long-term disease management. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government body, 6,008 HIV diagnoses were reported in England in 2023 (including individuals previously diagnosed abroad), representing a 51% increase from 3,975 cases in 2022. Therefore, the rising prevalence of HIV/AIDS is contributing to the growth of the cryptococcosis therapeutics market.

The growth in healthcare expenditure is also expected to propel the expansion of the cryptococcosis therapeutics market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, healthcare infrastructure, research, and public health programs aimed at improving health outcomes. Rising healthcare expenditure is largely driven by the aging global population, which increases demand for medical care, advanced treatments, and long-term health services. Higher healthcare spending supports the cryptococcosis therapeutics market by improving access to advanced antifungal treatments, enabling earlier diagnosis, and funding research into more effective therapies. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services (CMS), a US-based federal agency, national health expenditures increased by 7.5% to $4.9 trillion in 2023, accounting for 17.6% of the country's gross domestic product (GDP). Additionally, national health expenditures are projected to grow at an average annual rate of 5.6% between 2023 and 2032, raising healthcare spending as a share of GDP from 17.3% in 2022 to 19.7% by 2032. Therefore, rising healthcare expenditure is driving the growth of the cryptococcosis therapeutics market.

Major companies operating in the cryptococcosis therapeutics market are prioritizing clinical trials to develop innovative treatment options, such as oral lipid-nanocrystal (LNC) formulations, to improve treatment accessibility, reduce toxicity, and enhance patient outcomes. Oral lipid-nanocrystal formulations are advanced drug-delivery systems that encapsulate medications within lipid-based nanocrystals, enabling oral administration while improving tissue targeting, including penetration into the central nervous system, and minimizing kidney toxicity compared to conventional intravenous therapies. For instance, in March 2023, Matinas BioPharma Holdings, Inc., a US-based biopharmaceutical company, presented MAT2203, its oral LNC formulation of amphotericin B, at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Results from the Phase 2 EnACT trial showed that MAT2203 achieved mean early fungicidal activity above the study's primary threshold, delivered approximately 95% two-week survival in an all-oral cohort of 40 patients, and demonstrated no evidence of kidney toxicity after six weeks of treatment. By utilizing Matinas' proprietary LNC platform to convert a traditionally intravenous antifungal therapy into an oral formulation, MAT2203 highlights the potential to transform the current IV-based treatment approach for cryptococcosis.

Major companies operating in the cryptococcosis therapeutics market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Basilea Pharmaceutica AG, F2G Limited, Century Pharmaceuticals Ltd., LGM Pharma LLC, Zeon Health Industries Pvt. Ltd., Matinas BioPharma Holdings Inc.

North America was the largest region in the cryptococcosis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cryptococcosis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cryptococcosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cryptococcosis therapeutics market consists of revenues earned by entities by providing services such as diagnosis, antifungal drug administration, patient monitoring, treatment planning, disease management, and post-treatment care. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis therapeutics market also includes sales of polyene antifungals, azole antifungals, pyrimidine analogues, protein/enzyme inhibitors, and repurposed drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cryptococcosis Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cryptococcosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cryptococcosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cryptococcosis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Branded; Generic
• 2) By Treatment: Amphotericin B; Flucytosine; Fluconazole; Other Treatments
• 3) By Route Of Administration: Oral; Intravenous; Inhalation
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Branded Drugs: Ambisome; Diflucan; Vfend; Noxafil; Cresemba
• 2) By Generic Drugs: Amphotericin B Deoxycholate; Fluconazole; Flucytosine
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Gilead Sciences Inc.; Asahi Kasei Pharma Corporation; Astellas Pharma Inc.; Sun Pharmaceutical Industries Limited; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Basilea Pharmaceutica AG; F2G Limited; Century Pharmaceuticals Ltd.; LGM Pharma LLC; Zeon Health Industries Pvt. Ltd.; Matinas BioPharma Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Cryptococcosis Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Cryptococcosis Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Cryptococcosis Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Cryptococcosis Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Generic Antifungal Drugs
  • 4.2.2 Increasing Preference For Intravenous Administration In Severe Cases
  • 4.2.3 Expansion Of Online And Retail Pharmacy Distribution Channels
  • 4.2.4 Growing Focus On Early Diagnosis And Treatment Of Cryptococcosis
  • 4.2.5 Development Of Combination Therapies And Novel Formulations

5. Cryptococcosis Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Ambulatory Surgical Centers
• 5.3 Clinics And Healthcare Facilities
• 5.4 Online Pharmacy Providers
• 5.5 Research And Diagnostic Laboratories

6. Cryptococcosis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cryptococcosis Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Cryptococcosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Cryptococcosis Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Cryptococcosis Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Cryptococcosis Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cryptococcosis Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cryptococcosis Therapeutics Market Segmentation

• 9.1. Global Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Branded, Generic
• 9.2. Global Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amphotericin B, Flucytosine, Fluconazole, Other Treatments
• 9.3. Global Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Inhalation
• 9.4. Global Cryptococcosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.5. Global Cryptococcosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Surgical Centers, Other End Users
• 9.6. Global Cryptococcosis Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ambisome, Diflucan, Vfend, Noxafil, Cresemba
• 9.7. Global Cryptococcosis Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amphotericin B Deoxycholate, Fluconazole, Flucytosine

10. Cryptococcosis Therapeutics Market Regional And Country Analysis

• 10.1. Global Cryptococcosis Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Cryptococcosis Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cryptococcosis Therapeutics Market

• 11.1. Asia-Pacific Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cryptococcosis Therapeutics Market

• 12.1. China Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cryptococcosis Therapeutics Market

• 13.1. India Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cryptococcosis Therapeutics Market

• 14.1. Japan Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cryptococcosis Therapeutics Market

• 15.1. Australia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cryptococcosis Therapeutics Market

• 16.1. Indonesia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cryptococcosis Therapeutics Market

• 17.1. South Korea Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cryptococcosis Therapeutics Market

• 18.1. Taiwan Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cryptococcosis Therapeutics Market

• 19.1. South East Asia Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cryptococcosis Therapeutics Market

• 20.1. Western Europe Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cryptococcosis Therapeutics Market

• 21.1. UK Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cryptococcosis Therapeutics Market

• 22.1. Germany Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cryptococcosis Therapeutics Market

• 23.1. France Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cryptococcosis Therapeutics Market

• 24.1. Italy Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cryptococcosis Therapeutics Market

• 25.1. Spain Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cryptococcosis Therapeutics Market

• 26.1. Eastern Europe Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cryptococcosis Therapeutics Market

• 27.1. Russia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cryptococcosis Therapeutics Market

• 28.1. North America Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cryptococcosis Therapeutics Market

• 29.1. USA Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cryptococcosis Therapeutics Market

• 30.1. Canada Cryptococcosis Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cryptococcosis Therapeutics Market

• 31.1. South America Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cryptococcosis Therapeutics Market

• 32.1. Brazil Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cryptococcosis Therapeutics Market

• 33.1. Middle East Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cryptococcosis Therapeutics Market

• 34.1. Africa Cryptococcosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cryptococcosis Therapeutics Market Regulatory and Investment Landscape

36. Cryptococcosis Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Cryptococcosis Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Cryptococcosis Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Cryptococcosis Therapeutics Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Asahi Kasei Pharma Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Cryptococcosis Therapeutics Market Other Major And Innovative Companies

• Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Basilea Pharmaceutica AG, F2G Limited, Century Pharmaceuticals Ltd., LGM Pharma LLC, Zeon Health Industries Pvt. Ltd., Matinas BioPharma Holdings Inc.

38. Global Cryptococcosis Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Cryptococcosis Therapeutics Market

40. Cryptococcosis Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Cryptococcosis Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Cryptococcosis Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Cryptococcosis Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer